Editorial

Ushering in a New Era of Asthma Management — Global Innovations and India's Imperative

Asthma, a chronic respiratory ailment affecting over 260 million individuals globally, remains a significant public health challenge. India bears a disproportionate burden, accounting for approximately 13% of global cases and 42% of asthma-related deaths, underscoring the urgent need for innovative and accessible treatments.

Advancements in Biologic Therapies :

Recent clinical trials have spotlighted benralizumab, a monoclonal antibody, as a promising treatment for acute eosinophilic exacerbations of asthma. Published in The Lancet Respiratory Medicine, the study demonstrated that benralizumab significantly reduced treatment failures compared to standard corticosteroid therapy, marking a potential paradigm shift in managing severe asthma cases.

The trial, known as the Acute exacerbations treated with BenRAlizumab Study (ABRA), included patients with asthma, COPD, or both, with an eosinophilic endotype. Benralizumab's targeted mechanism of action, focusing on interleukin-5 receptor-α, offers a more precise approach to reducing eosinophilic inflammation, potentially leading to better patient outcomes and fewer side effects compared to systemic corticosteroids.

TOUCH RESPIRATORY

Triple-Combination Inhalers : A New Standard

AstraZeneca's Breztri Aerosphere, a triple-combination inhaler comprising budesonide, glycopyrronium, and formoterol, has achieved all primary endpoints in Phase III trials for uncontrolled asthma. The KALOS and LOGOS studies reported significant improvements in lung function, suggesting that Breztri could redefine standard asthma care.

Already approved for use in treating Chronic Obstructive Pulmonary Disease (COPD), Breztri's success in asthma trials indicates its potential to become a mainstay in asthma management. The inhaler's ability to deliver a combination of anti-inflammatory and bronchodilatory effects in a single device simplifies treatment regimens, potentially improving patient adherence and outcomes.

Enhancing Access Through Biosimilars :

The US FDA's approval of Omlyclo, the first interchangeable biosimilar to

omalizumab (Xolair), represents a significant step toward making advanced biologic therapies more accessible and affordable. This development holds promise for broader treatment options, especially in resource-constrained settings.

Omlyclo's approval was supported by positive phase III data demonstrating comparable efficacy and safety profiles with the reference product Xolair. The availability of biosimilars like Omlyclo can enhance accessibility and affordability of biologic therapies for patients with severe persistent allergic asthma.

Personalized Medicine and AI Integration :

Diag-Nose.io, an Australian biotech firm, is pioneering the use of artificial intelligence in asthma management through its RhinoMAP platform. By analyzing nasal liquid biopsy samples, RhinoMAP aims to tailor treatments based on individual biological profiles, potentially enhancing treatment efficacy and reducing healthcare costs.

The company's flagship product, the ABEL Microsampler, enables precise, non-invasive collection of nasal samples for omics-grade analysis. This innovation holds promise for reducing medical costs and improving health outcomes.

India's Path Forward :

Given the high prevalence and mortality associated with asthma in India, integrating these global advancements into national healthcare strategies is imperative. Emphasizing early diagnosis, expanding access to biologic therapies, and adopting AI-driven personalized medicine could significantly improve patient outcomes. Moreover, public health initiatives focusing on education and awareness are crucial to destigmatize the disease and encourage timely medical intervention.

Addressing asthma in India requires focused efforts on improving air quality, early diagnosis, and effective management strategies to reduce the disease burden. Urbanization and lifestyle changes have led to an increasing number of asthma cases, particularly among children and adolescents in urbanized areas. Occupational hazards, such as exposure to dust, chemicals, and pollutants, also contribute to higher asthma risks among farmers, factory workers, and construction workers.

In conclusion, the convergence of innovative therapies and technologies heralds a transformative era in asthma management. For India, embracing these advancements and tailoring them to the local context is essential to alleviate the burden of asthma and enhance the quality of life for millions.

Hony Editor, JIMA **Kakali Sen**